Countable Labs develops Countable PCR, a single-molecule quantification technology that the company says delivers at least 10x the sensitivity of conventional PCR and offers broad dynamic range, multiplexing, and molecular linkage capabilities. The platform is purpose-built for applications across research, translational science, and industrial testing, and the company highlights use cases including cell and gene therapy, oncology, molecular diagnostics, MRD testing, and vaccine quality control. Countable PCR is described as providing superior sensitivity and precision relative to digital PCR and next-generation sequencing, with no Poisson correction or standard curves. The company plans to develop fit-for-purpose 10-color solutions and pursue global commercial expansion, supported by the recent $26 million financing. Countable Labs is privately held, founded in 2019, and headquartered in Palo Alto, California.

Total raised

$26M

Funding rounds

1

Latest round

Equity

Latest activity

May 2026